Ispecimen Inc. (ISPC) Stock Price & Analysis
Ispecimen Inc. (ISPC) rose 0.00% to USD 1.54 as of September 8, 2026 at 07:36 UTC, according to Nexqual real-time market data.
ISPC last closed at USD 1.54; the session ranged USD 1.51–1.57 on volume of 1,446,658 shares. Market capitalization is —, with a 52-week range of USD 1.4–127.2 (NCM). Source: Nexqual, September 8, 2026 at 07:36 UTC.
Key Statistics (as of September 8, 2026 at 07:36 UTC)
| Price | USD 1.54 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.54 |
| Open | USD 1.54 |
| Day Range | USD 1.51 – 1.57 |
| 52-Week Range | USD 1.4 – 127.2 |
| Volume | 1,446,658 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (ISPC)
Nexqual's technical model rates ISPC "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 07:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.51 (neutral) |
| vs SMA50 | Below (USD 2.12) |
| MACD | -0.2 (negative) |
From Ispecimen Inc.'s Latest SEC 10-K Filing (filed 2026-04-01)
Key Strengths & Strategy (as disclosed to the SEC)
- The competitive organizations, including:             In each of these cases, the landscape is extraordinarily fragmented, and our management estimates that most biospecimen providers have less than 5% market share each, and no single biospecimen provider has more than a 20% market share.
- While we currently do not have any patents protecting our intellectual property, we rely on a combination of copyright, trademark, and trade secret laws in the United States and other jurisdictions, as well as confidentiality and non-disclosure agreements and other contractual protections with employees and third parties to protect our intellectual property rights, including our proprietary technology, brand, and know-how.
- The GDPR regulates the collection, use, disclosure, transfer, and/or other processing of personal data of identified or identifiable individuals located in the European Economic Areas, including the European Union ("EU").
- As part of this continued platform evolution, iSpecimen continues to explore adjacencies that leverage the platform including a data as a product model.   Our Technology   Technology Components   The legacy iSpecimen Marketplace has been operational for many years as an external-facing platform designed to facilitate search and matching between researchers and suppliers.
Partnerships
- We contract once with each participating customer and with each supplier organization and a single agreement then enables all users in that organization to instantly connect and work with all other organizations in the iSpecimen network.
- Recently, the Company made a strategic investment in a new technology platform built on its SalesStack solution to modernize the legacy system.   This new system introduces a cloud-native, next-generation architecture, providing a more secure, scalable, and efficient foundation for the Marketplace.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BFRI | Biofrontera Inc. | USD 1.61 | ▲ 5.92% |
| LGVN | Longeveron Inc. | USD 6.81 | ▲ 0.44% |
| PTPI | Petros Pharmaceuticals, Inc. | USD 0.01 | ▲ 20% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.58 | ▲ 0% |
| SOPAQ | Society Pass Incorporated | USD 0 | ▼ 33.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:36 UTC. This page is informational and not investment advice.